Extracellular proteolysis and angiogenesis

Thrombosis and Haemostasis

Volumn 86, Issue 1, 2001, Pages 346-355

  Pepper, M S ^a  

^a UNIVERSITY OF GENEVA MEDICAL SCHOOL   (Switzerland)

Author keywords

Angiostatin; Endostatin; Matrix; Metalloproteinase; Plasminogen

Indexed keywords

ANGIOSTATIN; ENDOSTATIN; MATRIX METALLOPROTEINASE; PLASMIN; PLASMINOGEN ACTIVATOR;

ANGIOGENESIS; BLOOD AND HEMOPOIETIC SYSTEM; CONFERENCE PAPER; EXTRACELLULAR MATRIX; FUNCTIONAL ASSESSMENT; GROWTH INHIBITION; HUMAN; MOLECULAR BIOLOGY; MOLECULAR DYNAMICS; MOLECULAR INTERACTION; NEOVASCULARIZATION (PATHOLOGY); PLASMINOGEN ACTIVATION; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN SYNTHESIS INHIBITION; REGULATORY MECHANISM; TUMOR GROWTH;

EID: 0034923623     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1616232     Document Type: Conference Paper

References (153)

1. Manipulating angiogenesis: From basic science to the bedside
2. The plasminogen activation system in tumor growth, invasion, and metastasis
3. Matrix metalloproteinases: Effectors of development and normal physiology
4. Tumor progression and angiogenesis: Cathepsin B and Co.
5. Involvement of cysteine proteases in bFGF-induced angiogenesis in guinea pig and rat cornea
6. Mammalian heparanase as mediator of tumor metastasis and angiogenesis
7. Tumor angiogenesis: The role of oncogenes and tumor suppressor genes
8. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis
9. Vascular permeability factor/vascular endothelial growth factor and the significance of microvascular hyperpermeability in angiogenesis
10. Vascular endothelial growth factor: Molecular and biological aspects
11. Fibroblast growth factor 2: Its structure and property, paracrine function, tumor angiogenesis, and prostate-related mitogenic and oncogenic functions
12. Function of fibroblast growth factors and vascular endothelial growth factors and their receptors in angiogenesis
13. Potent synergism between vascular endothelial growth factor and basic fibroblast growth factor in the induction of angiogenesis in vitro
14. Synergistic effects of vascular endothelial growth factor and basic fibroblast growth factor on the proliferation and cord formation of bovine capillary endothelial cells within collagen gels
15. Synergistic effect of vascular endothelial growth factor and basic fibroblast growth factor on angiogenesis in vivo
16. Suppression of VEGF-induced angiogenesis by the protein tyrosine kinase inhibitor, lavendustin. A.
17. Anticancer drug targets: Approaching angiogenesis
18. Proteolytic balance and capillary morphogenesis
19. Angiogenesis: A paradigm for balanced extracellular proteolysis during cell migration and morphogenesis
20. Increased proteolytic activity is responsible for the aberrant morphogenetic behaviour and of endothelial cells expressing middle T oncogene
21. The matrix metalloproteinase family
22. Matrix metalloproteinases in tumor invasion
23. Tissue inhibitors of metalloproteinases: Evolution, structure and function
24. Membrane-type metalloproteinases
25. Mechanisms for pro matrix metalloproteinase activation
26. Matrix metalloproteinases in angiogenesis: A moving target for therapeutic intervention
27. Matrix metalloproteinases: Pro- and anti-angiogenic activities
28. The role of matrix metalloproteinase activity in the maturation of human capillary endothelial cells in vivo
29. Regulation of vascular growth and regression by matrix metalloproteinases in the rat aorta model of angiogenesis
30. Controlling tumor angiogenesis and metastasis of C26 murine colon adenocarcinoma by a new matrix metalloproteinase inhibitor, KB-R7785, in two tumor models
31. Correlation of anti-angeogenic and antitumor efficacy of N-biphenyl sulfonyl-phenylalanine hydroxiamic acid (BPHA), an orally-active, selective matrix metalloproteinase inhibitor
32. Matrix metalloproteinase-2 is required for the switch to the angiogenic phenotype in a tumor model
33. Turmor targeting with a selective gelatinase inhibitor
34. Disruption of angiogenesis by PEX, a noncatalytic metalloproteinase fragment with integrin binding activity
35. Suppression of angiogenesis by lentiviral delivery of PEX, a noncatalytic fragment of matrix metalloproteinase 2
36. Disruption of matrix metalloproteinase 2 binding to integrin alpha v beta 3 by an organic molecule inhibits angiogenesis and tumor growth in vivo
37. Unaltered secretion of beta-amyloid precursor in gelatinase A (matrix metalloproteinase 2)-deficient mice
38. MMP-9/gelatinase B is a likely regulator of growth plate angiogenesis and apoptosis of hypertrophic chondrocytes
39. Reduced angiogenesis and progression in gelatinase A-deficient mice
40. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis
41. MT1-MMP-deficient mice develop dwarfism, osteopenia, arthritis, and connective tissue disease due to inadequate collagen turnover
42. Impaired enchondral ossification and angiogenesis in mice deficient in membrane-type matrix metalloproteinase I
43. Matrix metalloproteinase requirement during angiogenesis in vitro: A comparative study in collagen and fibrin gels
44. Inhibition of angiogenesis by tissue inhibitor of metalloproteinase-3 (TIMP-3)
45. The plasminogen (fibrinolytic) system
46. Phorbol ester induces cultured endothelial cells to invade a fibrin matrix in the presence of fibrinolytic inhibitors
47. Matrix metalloproteinases regulate neovascularization by acting as pericellular fibrinolysins
48. Regulation of cell invasion and morphogenesis in a three-dimensional type I colagen matrix by membrane-type matrix metalloproteinase 1, 2, and 3
49. Transgenic mouse models in angiogenesis and cardiovascular disease
50. Urokinase receptor expression on human microvascular endothelial cells is increased by hypoxia: Implications for capillary-like tube formation in a fibrin matrix
51. Hypoxia induces transcription of the plasminogen activator inhibitor-1 gene through genistein-sensitive tyrosine kinase pathways in vascular endothelial cells
52. Urokinase-type plasminogen activator is induced in migrating capillary endothelial cells
53. Plasminogen activator inhibitor-1 is induced in migrating endothelial cells
54. Upregulation of urokinase receptor expression on migrating endothelial cells
55. Apposition-dependent induciton of plasminogen activator inhibitor type-1 expression: A mechanism for balancing pericellular proteolysis during angiogenesis
56. Lymphangiogenesis and tumor metastasis: Myth or reality
57. In vitro angiogenic and proteolytic properties of bovine lymphatic endothelial cells
58. Vascular endothelial growth factor (VEGF)-C synergises with basic fibroblast growth factor and VEGF in the induction of angiogenesis in vitro, and alters endothelial cell proteolytic properties
59. The regulatory effects of cytokines on lymphatic angiogenesis
60. Stimulation of plasminogen activator and inhibitor in the lymphatic endothelium
61. Impaired wound healing in mice with a disrupted plasminogen gene
62. Expression of plasminogen activator inhibitor type 1 by human prostate carcinoma cells inhibits primary tumor growth, tumor-associated angiogenesis, and metastasis to lung and liver in an athymic mouse model
63. Inhibition of plasminogen activators or matrix metalloproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure
64. Plasminogen activator (urokinase) causes vascularization of the cornea
65. Plasminogen activators (urokinase) mediate neovascularization: Possible role in tumor angiogenesis
66. Urokinase-dependent angiogenesis in vitro and diacylglycerol production ar blocked by antisense oligonucleotides against the urokinase receptor
67. In vivo angiogenic activity of urokinase: Role of endogenous fibroblast growth factor-2
68. Urokinase receptor antagonists inhibit angiogenesis and primary tumor growth in syngeneic mice
69. Adenovirus-mediated delivery of a uPA/uPAR antagonist suppresses angiogenesis-dependent tumor growth and dissemination in mice
70. Inhibition of prostate cancer neovasculatization and growth by urokinas-plasminogen activator receptor blockade
71. A peptide derived from the nonreceptor binding region of urokinase plasminogen activator (uPA) inhibits tumor progression and angiogenesis and induces tumor cell death in vivo
72. A peptide derived from the non-receptor-binding regionof urokinase plasminogen activator inhibits gliobalstoma growth and angiogenesis in vivo in combination with cisplatin
73. Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization
74. Tumor development is retarded in mice lacking the gene for urokinase-type plasminogen activator of its inhibitor, plasminogen activator inhibitor-1
75. Regulation of cell adhesion by PAI-1
76. Urokinase receptor and integrin partnership: Coordination of signalling for cell adhesion, migration and growth
77. Urokinase receptor: A molecular organizer in cellular communication
78. Localization of tissue plasminogen activator in the endothelium of a limited number of vessels
79. A role of fibrinolytic activity in angiogenesis. Quantitative assay using in vitro model
80. Indispensable role of tissue-type plasminogen activator in growth factor-dependent tube formation of human microvascular endothelial cells in vitro
81. Expression of tissue-type plasminogen activator and its inhibitor couples with development of capillary network by human microvascular endothelial cells on Matrigel
82. Synergistic induction of tissue-type plasminogen activator (tPA) by vascular endothelial growth factor and basic fibroblast growth factor and localization of tPA to Weibel-Palade bodies in bovine microvascular endothelial cells
83. Posttranscriptional stimulation of endothelial cell matrix metalloproteinases 2 and 1 by endothelioma cells
84. Angiostatin: A circulating endothelial cell inhibitor that suppresses angiogenesis and tumor growth
85. Therapeutic potentials of angiostatin in the treament of cancer
86. Endostatin: A promising drug for antiangiogenic therapy
87. Anti-angiogenic cues from vascular basement membrane collagen
88. Canstatin, a novel matrix-derived inhibitor of angiogenesis and tumor growth
89. Distinct antitumor properties of a type IV collagen domain derived from basement membrane
90. Two RGD-independent alpha vbeta 3 in integrin binding sites on tumstatin regulate distinct anti-tumor properties
91. Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma
92. Kringle domains of human angiostatin
93. Kringle 5 of plaminogen is a novel inhibitor of endothelial cell growth
94. Suppression of angiogenesis and tumor growth by the inhibitor K1-5 generated by plasmin-mediated proteolysis
95. Selective inhibition by kringle 5 of human plasminogen on endothelial cell migration, an important process in angiogenesis
96. Characterization of kringle domains of angiostatin as antagonists of endothelial cell migration, an important process in angiogenesis
97. Macrophage-derived metalloelastase is responsible for the generation of angiostatin in Lewis lung carcinoma
98. Angiostatin-converting enzyme activities of human matrilysin (MMP-7) and gelatinase B/Type IV collagenase (MMP-9)
99. Matrix metalloproteinases generate angiostatin: Effects on neovascularization
100. Generation of an angiostatin-like fragment from plasminogen by stromelysin-1 (MMP-3)
101. Generation of angiostatin-like fragments from plasminogen by prostate-specific antigen
102. Angiostatin generated by cathepsin D secreted by human prostate carcinoma cells
103. Generation of angiostatin by reduction and proteolysis of plasmin. Catalysis by a plasmin reductase secreted by cultured cells
104. Angiostatin formation involves disulfide bond reduction and proteolysis in kringle 5 of plasmin
105. Human prostate carcinoma cells express enzymatic activity that converts human plasminogen to the angiogenesis inhibitor, angiostatin
106. The mechanism of cancer-mediated conversion of plasminogen to the angiogenesis inhibitor, angiostatin
107. A recombinant human angiostatin protein inhibits experimental primary and metastatic cancer
108. Suppression of tumor growth with recombinant murine angiostatin
109. Angiostatin induces endothelial cell apoptosis and activation of focal adhesion kinase independently of the integrin-binding motif RGD
110. Angiostatin inhibits endothelial and melanoma cellular invasion by blocking matrix-enhanced plasminogen activation
111. In vitro tumor angiogenesis assays: Plasminogen lysine binding site 1 inhibits in vitro tumor-induced angiogenesis
112. Angiostatin gene transfer: Inhibition of tumor growth in vivo by blockage of endothelial cell proliferation associated with a mitosis arrest
113. Multiple forms of angiostatin induce apoptosis in endothelial cells
114. Angiostatin binds ATP synthase on the surface of human endothelial cells
115. Angiostatin induces and sustains dormancy of human primary tumors in mice
116. Human angiostatin inhibits murine hemangioendothelioma tumor growth in vivo
117. Angiostatin suppresses malignant glioma growth in vivo
118. Expression of angiostatin cDNA in a murine fibrosarcoma suppresses primary tumor growth and produces long-term dormancy of metastases
119. Combined effects of radiotherapy and angiostatin gene therapy in glioma tumor model
120. Liposome-delivered angiostatin strongly inhibits tumor growth and metastatization in a transgenic model of spontaneous breast cancer
121. Endostatin: An endogenous inhibitor of angiogenesis and tumor growth
122. Structure, function and tissue forms of the C-terminal globular domain of collagen XVIII containing the angiogenesis inhibitor endostatin
123. The generation of endostatin is mediated elastase
124. Secreted cathepsin L generates endosatin from L generates endostatin from collagen XVIII
125. Generation and degradation of human endostatin proteins by various proteinases
126. Cloning, expression and vitro activity of human endostatin
127. Endostatin inhibits microvessel formation in the ex vivo rat aortic ring assay
128. Angiogenesis inhibitor endostatin is a direct component of elastic fibres in vessel walls
129. Endostatin binds to blood vessels in situ independent of heparin sulfate and does not compete for fibroblast growth factor-2 binding
130. Structural basis and potential role of heparin/heparan sulfate binding to the angiogenesis inhibitor endostatin
131. Crystal structure of the angiogenesis inhibitor andostatin 1.5 Å resolution
132. Isolation and characterization of the circulating form of human endostatin
133. Endostatin: Yeast production, mutants, and antitumor effect in renal carcinoma
134. Inhibitory effect of full-length human endostatin on in vitro angiogenesis
135. The angiogenesis inhibitor, endostatin, does not affect murine cutaneous wound healing
136. Endostatin inhibits endothelial and tumor cellular invasion by blocking the activation and catalytic activity of matrix metalloproteinase 2
137. Adenovirus-mediated gene transfer of endostatin in vivo results in high level of transgene expression and inhibition of tumor growth and metastases
138. Continuous release of endostatin from microencapsulated engineered cells for tumor therapy
139. Endostatin inhibits VEGF-induced endothelial cell migration and tumor growth independently of zinc binding
140. Endostatin induces endothelial cell apoptosis
141. Synergy between angiostatin and endostatin: Inhibition of ovarian cancer growth
142. Systemic inhibition of tumor growth and tumor metastases by intramuscular administration of the endostatin gene
143. The angiogenesis inhibitor endostatin impairs blood vessel maturation during wound healing
144. Antitumor activities of endostatin against carcinogen-induced rat primary mammary tumors
145. Mouse endostatin inhibits the formation of lung and liver metastases
146. Antiangiogenic gene therapy of cancer utilizing a recombinant adenovirus to elevate systemic endostatin levels in mice
147. Local endostatin treatment of gliomas administered by microencapsulated producer cells
148. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance
149. Angiogenesis inhibitors endostatin or TNP-470 reduce intimal neovascularization and plaque growth in apolipoprotein E-deficient mice
150. Combined effects of angiostatin and ionizing radiation in antitumor therapy
151. Potentiation of the antitumor effect of ionizing radiation by brief concomitant expsosures to angiostatin
152. Angiogenesis: Potentials for pharmacologic intervention in the treatment of cancer, cardiovascular diseases, and chronic inflammation
153. Clinical studies with matrix metalloproteinase inhibitors